Document is current
Any future updates will be listed below
-
Authors
Xian, Hongxu
Watari, Kosuke https://orcid.org/0000-0003-0260-2323
Ohira, Masafumi
Brito, Jonathan S.
He, Peng
Onyuru, Janset
Zuniga, Elina I. https://orcid.org/0000-0001-8699-1623
Hoffman, Hal M.
Karin, Michael https://orcid.org/0000-0002-2758-6473
-
Funding
Funding for this research was provided by:
NIH United States
Arthritis National Research Foundation (#1291101)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI145314)
US NIH
NIH
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 2 May 2025
First Online: 17 June 2025
Competing interests
: M.K. is a founder of Elgia Pharmaceuticals and received research support from Gossamer Bio and Jansen Pharmaceuticals. M.K. holds an interest in PF-06835375, a TFH cell-depleting CXCR5 antibody. H.M.H. is a consultant for SOBI and Akros and received research funds from Takeda and Inapill. The other authors declare no competing interests.
